ARTICLE | Analyst Picks & Changes
Analyst picks & changes
July 6, 1993 7:00 AM UTC
Oppenheimer & Co. analyst Jeffrey Casdin initiated coverage with a "buy" rating based on the blockbuster potential of two new products, IL-11 platelet stimulator and IL-12 anti-cancer and anti-infective cytokine. IL-12 is cross-licensed with ...